

## DAFTAR PUSTAKA

1. Di Gennaro F, Pizzol D, Marotta C, Antunes M, Racalbutto V, Veronese N, et al. Coronavirus diseases (COVID-19) current status and future perspectives: A narrative review. *Int J Environ Res Public Health*. 2020;17(8).
2. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The incubation period of coronavirus disease 2019 (CoVID-19) from publicly reported confirmed cases: Estimation and application. *Ann Intern Med*. 2020;172(9):577–82.
3. World Health Organization. WHO Coronavirus (COVID-19) Dashboard [Internet]. WHO. 2022 [cited 2022 Sep 30]. Available from: <https://covid19.who.int/>
4. Pusdatin Kementerian Kesehatan. Data positif berdasarkan provinsi, jenis kelamin, usia, gejala, dan komorbid [Internet]. Kementerian Kesehatan. 2022 [cited 2022 Sep 30]. Available from: <https://covid19.go.id/peta-sebaran>
5. Kikkenborg Berg S, Dam Nielsen S, Nygaard U, Bundgaard H, Palm P, Rotvig C, et al. Long COVID symptoms in SARS-CoV-2-positive adolescents and matched controls (LongCOVIDKidsDK): a national, cross-sectional study. *Lancet Child Adolesc Heal* [Internet]. 2022;6(4):240–8. Available from: [http://dx.doi.org/10.1016/S2352-4642\(22\)00004-9](http://dx.doi.org/10.1016/S2352-4642(22)00004-9)
6. Yasuhara J, Kuno T, Takagi H, Sumitomo N. Clinical characteristics of COVID-19 in children: A systematic review. *Pediatr Pulmonol*. 2020;55(10):2565–75.
7. García-Salido A, Vicente JC de C, Hofheinz SB, Ramírez JB, María Slöcker Barrio I, Leóz Gordillo A, et al. Severe manifestations of SARS-CoV-2 in children and adolescents: from COVID-19 pneumonia to multisystem inflammatory syndrome: a multicentre study in pediatric intensive care units in Spain. *Crit Care*. 2020;24(666):1–13.
8. Putri ND, Prawira Y, Tartila T, Jasin MR, Puspitasari HA, Puspaningtyas NW, et al. Clinical Features of Multisystem Inflammatory Syndrome in Children Associated with COVID-19 in Indonesia. *J Trop Pediatr*. 2022;68(3):1–12.
9. Center of Disease Control and Prevention. Reporting Multisystem Inflammatory Syndrome in Children (MIS-C). 2020;1. Available from: <https://www.cdc.gov/mis-c/pdfs/hcp/MIS-Children-Handout-FINAL.pdf>
10. Sözeri B, Çağlayan Ş, Atasayan V, Ulu K, Coşkuner T, Pelin Akbay Ö, et al. The clinical course and short-term health outcomes of multisystem inflammatory syndrome in children in the single pediatric rheumatology center. *Postgrad Med* [Internet]. 2021;133(8):994–1000. Available from: <https://doi.org/10.1080/00325481.2021.1987732>
11. World Health Organization. Multisystem inflammatory syndrome in children and adolescents with COVID-19 [Internet]. 2020 [cited 2022 Jan 3]. Available from: <https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19>
12. Hennon TR, Penque MD, Abdul-Aziz R, Alibrahim OS, McGreevy MB, Prout AJ, et al. COVID-19 associated Multisystem Inflammatory Syndrome

- in Children (MIS-C) guidelines; a Western New York approach. *Prog Pediatr Cardiol.* 2020;(January).
13. Consiglio CR, Cotugno N, Sardh F, Pou C, Amodio D, Rodriguez L, et al. The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19. *Cell.* 2020;183(4):968-981.e7.
  14. Centers for Disease Control and Prevention. Information for Healthcare Providers about Multisystem Inflammatory Syndrome in Children (MIS-C) [Internet]. CDC. 2021 [cited 2022 Apr 6]. Available from: <https://www.cdc.gov/mis/mis-c/hcp/>
  15. Rowley AH. Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children. *Nat Rev Immunol* [Internet]. 2020;20(8):453–4. Available from: <http://dx.doi.org/10.1038/s41577-020-0367-5>
  16. Malviya A, Mishra A. Childhood Multisystem Inflammatory Syndrome: An Emerging Disease with Prominent Cardiovascular Involvement—A Scoping Review. *SN Compr Clin Med.* 2021;3(1):48–59.
  17. Hosseini P, Fallahi MS, Erabi G, Pakdin M, Zarezadeh SM, Faridzadeh A, et al. Multisystem Inflammatory Syndrome and Autoimmune Diseases Following COVID-19: Molecular Mechanisms and Therapeutic Opportunities. *Front Mol Biosci.* 2022;9(April):1–21.
  18. Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, et al. Inflammatory responses and inflammation-associated diseases in organs. *Oncotarget.* 2018;9(6):7204–18.
  19. Ali A, Abbasi AS, Amjad T, Saleem F. Erythrocyte Sedimentation Rate And C-Reactive Protein As Marker Of Acute Versus Chronic Medical Conditions. *J Ayub Med Coll Abbottabad.* 2019;31(1):39–45.
  20. Shankaralingappa A, Thirunavukkarasu AB. Pathogenesis of COVID-19 and multi-system inflammatory syndrome in children. *Int J Contemp Pediatr.* 2021;8(4):777.
  21. Graciano-Machuca O, Villegas-Rivera G, López-Pérez I, Macías-Barragán J, Sifuentes-Franco S. Multisystem Inflammatory Syndrome in Children (MIS-C) Following SARS-CoV-2 Infection: Role of Oxidative Stress. *Front Immunol.* 2021;12:1–10.
  22. Litao MKS, Kamat D. Erythrocyte sedimentation rate and C-reactive protein: How best to use them in clinical practice. *Pediatr Ann.* 2014;43(10):417–20.
  23. Radhika Gulhar, Ashraf MA, Jialal I. Physiology, Acute Phase Reactants [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK519570/?report=classic>
  24. Jain S, Gautam V, Naseem S. Acute-phase proteins: As diagnostic tool. *J Pharm Bioallied Sci.* 2011;3(1):118–27.
  25. Zhao Y, Yin L, Patel J, Tang L, Huang Y. The inflammatory markers of multisystem inflammatory syndrome in children (MIS-C) and adolescents associated with COVID-19: A meta-analysis. *J Med Virol.* 2021;93(7):4358–69.
  26. Acevedo L, Piñeres-Olave BE, Niño-Serna LF, Vega LM, Gomez IJA, Chacón S, et al. Mortality and clinical characteristics of multisystem inflammatory syndrome in children (MIS-C) associated with covid-19 in critically ill patients: an observational multicenter study (MISCO study).

- BMC Pediatr [Internet]. 2021;21(1):1–12. Available from: <https://doi.org/10.1186/s12887-021-02974-9>
27. Vella LA, Giles JR, Baxter AE, Oldridge DA, Diorio C, Kuri-Cervantes L, et al. Deep immune profiling of MIS-C demonstrates marked but transient immune activation compared to adult and pediatric COVID-19. *Sci Immunol*. 2021;6(57):1–16.
  28. Sander LE, Sackett SD, Dierssen U, Beraza N, Linke RP, Müller M, et al. Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. *J Exp Med*. 2010;207(7):1453–64.
  29. Lapić I, Padoan A, Bozzato D, Plebani M. Erythrocyte sedimentation rate and c-reactive protein in acute inflammation: Meta-analysis of diagnostic accuracy studies. *Am J Clin Pathol*. 2020;153(1):14–29.
  30. Tishkowski K, Gupta V. Erythrocyte Sedimentation Rate [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK557485/>
  31. Fest J, Ruitter R, Mooijaart SP, Ikram MA, van Eijck CHJ, Stricker BH. Erythrocyte sedimentation rate as an independent prognostic marker for mortality: a prospective population-based cohort study. *J Intern Med*. 2019;285(3):341–8.
  32. Ramsay ES, Lerman MA. How to use the erythrocyte sedimentation rate in paediatrics. *Arch Dis Child Educ Pract Ed*. 2015;100(1):30–6.
  33. Abbag FI, Maree J, Qahtani A. Extreme elevation of the erythrocyte sedimentation rate in children. *Ann Saudi Med*. 2007;27:175–8.
  34. Royal College of Paediatrics and Child Health. Guidance paediatric multisystem inflammatory syndrome temporally associated with Cov-19. *R Coll Paediatr Child Heal*. 2020;1–6.
  35. Dufort EM, Koumans EH, Chow EJ, Rosenthal EM, Muse A, Rowlands J, et al. Multisystem Inflammatory Syndrome in Children in New York State. *N Engl J Med*. 2020;383(4):347–58.
  36. Payne AB, Gilani Z, Godfred-Cato S, Belay ED, Feldstein LR, Patel MM, et al. Incidence of Multisystem Inflammatory Syndrome in Children among US Persons Infected with SARS-CoV-2. *JAMA Netw Open*. 2021;4(6).
  37. Belay ED, Abrams J, Oster ME, Giovanni J, Pierce T, Meng L, et al. Trends in Geographic and Temporal Distribution of US Children with Multisystem Inflammatory Syndrome during the COVID-19 Pandemic. *JAMA Pediatr*. 2021;175(8):837–45.
  38. Levy M, Recher M, Hubert H, Javouhey E, Fléchelles O, Leteurtre S, et al. Multisystem Inflammatory Syndrome in Children by COVID-19 Vaccination Status of Adolescents in France. *JAMA*. 2021;327(3):281–2.
  39. Panigrahy N, Policarpio J, Ramanathan R. Multisystem inflammatory syndrome in children and SARS-CoV-2: A scoping review. *J Pediatr Rehabil Med*. 2020;13(3):301–16.
  40. Roarty C, Waterfield T. Review and future directions for PIMS-TS (MIS-C). *Arch Dis Child*. 2022;0(0):archdischild-2021-323143.
  41. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. *Nat Rev Microbiol*. 2021;19(3):141–54.
  42. Harrison AG, Lin T, Wang P. Mechanisms of SARS-CoV-2 Transmission



- and Pathogenesis. *Trends Immunol* [Internet]. 2020;41(12):1100–15. Available from: <https://doi.org/10.1016/j.it.2020.10.004>
43. Hasöksüz M, Kiliç S, Saraç F. Coronaviruses and sars-cov-2. *Turkish J Med Sci*. 2020;50(SI-1):549–56.
  44. Rampersad S, Tennant P. Replication and Expression Strategies of Viruses. *Viruses Mol Biol Host Interact Appl to Biotechnol*. 2018;(January):55–82.
  45. Satarker S, Nampoothiri M, Rahimi A, Mirzazadeh A, Tavakolpour S. Structural Proteins in Severe Acute Respiratory Syndrome Coronavirus-2. *Arch Med Res*. 2020;51(January):482–91.
  46. Huang Y, Yang C, Xu X feng, Xu W, Liu S wen. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. *Acta Pharmacol Sin* [Internet]. 2020;41(9):1141–9. Available from: <http://dx.doi.org/10.1038/s41401-020-0485-4>
  47. Farooq A, Alam F, Saeed A, Butt F, Khaliq MA, Malik A, et al. Multisystem Inflammatory Syndrome in Children and Adolescents (MIS-C) under the Setting of COVID-19: A Review of Clinical Presentation, Workup and Management. *Infect Dis Res Treat*. 2021;14:117863372110266.
  48. Baker SA, Kwok S, Berry GJ, Montine TJ. Angiotensin-converting enzyme 2 (ACE2) expression increases with age in patients requiring mechanical ventilation. *PLoS One* [Internet]. 2021;16(2 February):1–17. Available from: <http://dx.doi.org/10.1371/journal.pone.0247060>
  49. Jing X, Xu M, Song D, Yue T, Wang Y, Zhang P, et al. Association between inflammatory cytokines and anti-SARS-CoV-2 antibodies in hospitalized patients with COVID-19. *Immun Ageing*. 2022;19(1):1–17.
  50. Gruber CN, Patel RS, Trachtman R, Lepow L, Amanat F, Krammer F, et al. Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C). *Cell* [Internet]. 2020;183(4):982-995.e14. Available from: <https://doi.org/10.1016/j.cell.2020.09.034>
  51. Kovalchuk A, Wang B, Li D, Rodriguez-Juarez R, Ilnytskyy S, Kovalchuk I, et al. Fighting the Storm: Could Novel Anti-Tnf $\alpha$  And Anti-Il-6 C. Sativa Cultivars Tame Cytokine Storm in COVID-19? *Aging (Albany NY)*. 2021;13(2):1571–90.
  52. Bishara N. The Use of Biomarkers for Detection of Early- and Late-Onset Neonatal Sepsis. In: *Hematology, Immunology and Infectious Disease: Neonatology Questions and Controversies*. Elsevier; 2012. p. 303–15.
  53. Lawrensia S, Henrina J, Wijaya E, Suciadi LP, Saboe A, Cool CJ. Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2: a New Challenge amid the Pandemic. *SN Compr Clin Med*. 2020;2(11):2077–85.
  54. Kulkarni R. Antibody-Dependent Enhancement of Viral Infections. *Dynamics of Immune Activation in Viral Diseases*. Singapore: Springer, Singapore; 2020. 9–41 p.
  55. Arvin AM, Fink K, Schmid MA, Cathcart A, Spreafico R, Havenar-Daughton C, et al. A perspective on potential antibody-dependent enhancement of SARS-CoV-2. *Nature* [Internet]. 2020;584(7821):353–63. Available from: <http://dx.doi.org/10.1038/s41586-020-2538-8>

56. Lee WS, Wheatley AK, Kent SJ, DeKosky BJ. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. *Nat Microbiol* [Internet]. 2020;5(10):1185–91. Available from: <http://dx.doi.org/10.1038/s41564-020-00789-5>
57. Sánchez-Zuno GA, Matuz-Flores MG, González-Estevez G, Nicoletti F, Turrubiates-Hernández FJ, Mangano K, et al. A review: Antibody-dependent enhancement in COVID-19: The not so friendly side of antibodies. *Int J Immunopathol Pharmacol*. 2021;35:1–15.
58. Ikatan Dokter Anak Indonesia. Panduan Klinis Tata Laksana COVID-19 Pada Anak. 2020.
59. WHO. Global COVID-19 Clinical Platform: Case Report Form for suspected cases of Multisystem inflammatory syndrome (MIS) in children and adolescents temporally related to COVID-19. 2020.
60. Fernandes HP, Cesar CL, Barjas-Castro M de L. Electrical properties of the red blood cell membrane and immunohematological investigation. *Rev Bras Hematol Hemoter*. 2011;33(4):297–301.
61. Dyer EM, Waterfield T, Baynes H. How to use C-reactive protein. *Arch Dis Child Educ Pract Ed*. 2019;104(3):150–3.
62. Stringer D, Braude P, Myint PK, Evans L, Collins JT, Verduri A, et al. The role of C-reactive protein as a prognostic marker in COVID-19. *Int J Epidemiol*. 2021;50(2):420–9.
63. Vitamin and Mineral Nutrition Information System. C-reactive protein concentrations as a marker of inflammation or infection for interpreting biomarkers of micronutrient status. WHO. 2014;1–4.
64. Yale SH, Bray C, Bell LN, Liang H, Haykal R, Kaiksow F, et al. Erythrocyte Sedimentation Rate and C-reactive Protein Measurements and Their Relevance in Clinical Medicine. *Wis Med J*. 2016;115(6):317–21.
65. Cleland DA, Eranki AP. Procalcitonin [Internet]. Treasure Island (FL): StatPearls Publishing; 2021. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK539794/>
66. Morgenthaler NG, Struck J, Chancerelle Y, Weglöhner W, Agay D, Bohuon C, et al. Production of procalcitonin (PCT) in non-thyroidal tissue after LPS injection. *Horm Metab Res*. 2003;35(5):290–5.
67. Markanday A. Acute Phase Reactants in Infections: EvidenceBased Review and a Guide for Clinicians. *Open forum Infect Dis*. 2015;
68. Al-masoodi R, Abdullah U, Jassim H, Harun A. Immunomodulation Effect of Procalcitonin. *J Bacteriol Mycol*. 2019;6(4):1108.
69. Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK, Bassiri H, et al. Clinical Guidance for Pediatric Patients with Multisystem Inflammatory Syndrome in Children ( MIS-C ) Associated with SARS-CoV-2 and Hyperinflammation in COVID-19. 2022;(L):1–9.
70. American Academy of Pediatrics. Multisystem Inflammatory Syndrome in Children (MIS-C) Interim Guidance [Internet]. AAP Publishing. 2022 [cited 2022 Jul 18]. Available from: <https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/multisystem-inflammatory-syndrome-in-children-mis-c-interim-guidance/>
71. Kwak JH, Lee SY, Choi JW. Clinical features, diagnosis, and outcomes of multisystem inflammatory syndrome in children associated with coronavirus

- disease 2019. *Korean J Pediatr.* 2021;64(2):68–75.
72. Kaushik A, Gupta S, Sood M, Sharma S, Verma S. A systematic review of multisystem inflammatory syndrome in children associated with SARS-CoV-2 infection. *Pediatr Infect Dis J.* 2020;39(11):E340–6.
  73. Feldstein LR, Tenforde MW, Friedman KG, Newhams M, Rose EB, Dapul H, et al. Characteristics and Outcomes of US Children and Adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) Compared with Severe Acute COVID-19. *JAMA - J Am Med Assoc.* 2021;325(11):1074–87.
  74. Kotulska A, Kopeć-Mędrak M, Grosicka A, Kubicka M, Kucharz EJ. Correlation between erythrocyte sedimentation rate and C-reactive protein level in patients with rheumatic diseases. *Reumatologia.* 2015;53(5):243–6.
  75. Aini A, Nurmawan N, Ustiawaty J. Hubungan Antara Kadar Laju Endap Darah (LED) Dengan Kadar C-Reaktiv Protein (CRP) Pada Penderita Tuberkulosis (TBC) Di Wilayah Kerja Puskesmas Alas Barat. *J Anal Med Biosains.* 2020;7(1):34.
  76. Lanoix JP, Bourgeois AM, Schmidt J, Desblache J, Salle V, Smail A, et al. Serum procalcitonin does not differentiate between infection and disease flare in patients with systemic lupus erythematosus. *Lupus.* 2011;20(2):125–30.
  77. Turner D, Mack DR, Hyams J, LeLeiko N, Otley A, Markowitz J, et al. C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) or both? A systematic evaluation in pediatric ulcerative colitis. *J Crohn's Colitis [Internet].* 2011;5(5):423–9. Available from: <http://dx.doi.org/10.1016/j.crohns.2011.05.003>
  78. Abedini M, Delpisheh A, Nikkhu B, Vahabi A, Afkhamzadeh A. Procalcitonin and white blood cell count (WBC), erythrocyte sedimentation rate (ESR) and serum C-reactive protein (CRP) alterations in children with systemic inflammatory response syndrome before and after treatment. *African J Biotechnol.* 2012;11(49):10989–93.
  79. Tang Y, Li W, Baskota M, Zhou Q, Fu Z, Luo Z, et al. Multisystem inflammatory syndrome in children during the coronavirus disease 2019 (COVID-19) pandemic: a systematic review of published case studies. *Transl Pediatr.* 2021;10(1):121–35.
  80. Lin Q, Wu L, Lin W, Zhu L, Hu Y, Lin G, et al. Correlation between chest CT severity score and laboratory indicators in patients with Coronavirus disease 2019 (COVID-19). *Int J Clin Pract.* 2021;75(12):1–8.
  81. Fink EL, Robertson CL, Wainwright MS, Roa JD, Lovett ME, Stulce C, et al. Prevalence and Risk Factors of Neurologic Manifestations in Hospitalized Children Diagnosed with Acute SARS-CoV-2 or MIS-C. *Pediatr Neurol.* 2022;128:33–44.
  82. Whittaker E, Bamford A, Kenny J, Kaforou M, Jones CE, Shah P, et al. Clinical Characteristics of 58 Children with a Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2. *JAMA - J Am Med Assoc.* 2020;324(3):259–69.
  83. Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. *Nat Commun*



- [Internet]. 2020;11(1):1–10. Available from: <http://dx.doi.org/10.1038/s41467-020-19741-6>
84. Bowen A, Miller AD, Zambrano LD, Wu MJ, Oster ME, Godfred-Cato S, et al. Demographic and Clinical Factors Associated with Death among Persons <21 Years Old with Multisystem Inflammatory Syndrome in Children-United States, February 2020-March 2021. *Open Forum Infect Dis.* 2021;8(8):1–7.
  85. Lee KH, Li H, Lee MH, Park SJ, Kim JS, Han YJ, et al. Clinical characteristics and treatments of multi-system inflammatory syndrome in children: a systematic review. *Eur Rev Med Pharmacol Sci.* 2022;26(9):3342–50.
  86. Alkan G, Sert A, Oz SKT, Emiroglu M, Yılmaz R. Clinical features and outcome of MIS-C patients: an experience from Central Anatolia. *Clin Rheumatol* [Internet]. 2021;40(10):4179–89. Available from: <https://doi.org/10.1007/s10067-021-05754-z>
  87. Jia HP, Look DC, Shi L, Hickey M, Pewe L, Netland J, et al. ACE2 Receptor Expression and Severe Acute Respiratory Syndrome Coronavirus Infection Depend on Differentiation of Human Airway Epithelia. *J Virol.* 2005;79(23):14614–21.
  88. Bunyavanich S, Do A, Vicencio A. Nasal Gene Expression of Angiotensin-Converting Enzyme 2 in Children and Adults. *JAMA - J Am Med Assoc.* 2020;323(23):2427–9.
  89. Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. *N Engl J Med.* 2020;383(4):334–46.
  90. Morris SB, Belay E, Levin M, Schneider J, Marconi VC. Clinician Outreach and Communication Activity (COCA). In: *Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with Coronavirus Disease 2019 (COVID-19)* [Internet]. Centers of Disease Control and Prevention; 2020. Available from: [https://emergency.cdc.gov/coca/calls/2020/callinfo\\_051920.asp](https://emergency.cdc.gov/coca/calls/2020/callinfo_051920.asp)
  91. Mariani R, Liu H. Severe transient pancytopenia with dyserythropoiesis and dysmegakaryopoiesis in COVID-19-associated MIS-C. *Blood.* 2020;136(25):2964.
  92. Octavia L, Rachmalina R. Child Malnutrition during the COVID-19 Pandemic in Indonesia. 2022;25(4):347–50.
  93. NYC Department of Health. Health Department Announces Pediatric Obesity Outreach Campaign Targeting Pediatricians and Family Practitioners [Internet]. NYC Health. 2019 [cited 2022 Dec 22]. Available from: <https://www.nyc.gov/site/doh/about/press/pr2019/pediatric-obesity-outreach-campaign.page>
  94. Rah JH, Melse-Boonstra A, Agustina R, van Zutphen KG, Kraemer K. The Triple Burden of Malnutrition Among Adolescents in Indonesia. *Food Nutr Bull.* 2021;42(1S):S4–8.
  95. Chiang KC, Kalantar-Zadeh K, Gupta A. Thymic Dysfunction and Atrophy in COVID-19 Disease Complicated by Inflammation, Malnutrition and Cachexia. *Nutr Health.* 2022;28(2):199–206.
  96. Chou J, Thomas PG, Randolph AG. Immunology of SARS-CoV-2 infection

- in children. *Nat Immunol.* 2022;23(2):177–85.
97. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. *Nature* [Internet]. 2020;584(7821):430–6. Available from: <http://dx.doi.org/10.1038/s41586-020-2521-4>
  98. Magadum A, Kishore R. Cardiovascular Manifestations of COVID-19 Infection. *Cells.* 2020;9(11).
  99. Sayed IA, Bhalala U, Strom L, Tripathi S, Kim JS, Michaud K, et al. Gastrointestinal Manifestations in Hospitalized Children with Acute SARS-CoV-2 Infection and Multisystem Inflammatory Condition: An Analysis of the VIRUS COVID-19 Registry. *Pediatr Infect Dis J.* 2022;41(9):751–8.
  100. Hasan HA, Almubarak N, Jeber MA. the Relationship Between Esr and C-Reactive Protein With Variable Level of D-Dimer in Covid-19. *Wiad Lek.* 2021;74(12):3172–8.
  101. Abu Elkhashab AE, Swelem RS, Abd Alla AEDA, Hattata EA, Atta MS. Etiological and prognostic values of procalcitonin in hospital-acquired pneumonia. *Egypt J Chest Dis Tuberc* [Internet]. 2014;63(1):201–6. Available from: <http://dx.doi.org/10.1016/j.ejcdt.2013.09.015>
  102. Ito A, Ishida T. Diagnostic markers for community-acquired pneumonia. *Ann Transl Med.* 2020;8(9):609–609.
  103. Niehues T. C-reactive protein and other biomarkers—the sense and non-sense of using inflammation biomarkers for the diagnosis of severe bacterial infection. *LymphoSign J.* 2018;5(2):35–47.
  104. Prabhala S, Sivakoti S, Sahoo B. Utility of acute-phase reactants testing in clinical practice. *Indian J Community Fam Med.* 2021;7(1):12.
  105. Drăgoescu AN, Pădureanu V, Stănculescu AD, Chiuțu LC, Florescu DN, Gheonea IA, et al. Presepsin as a potential prognostic marker for sepsis according to actual practice guidelines. *J Pers Med.* 2021;11(1):1–9.
  106. Kurt C, Altunçekiç Yildirim A. Contribution of Erythrocyte Sedimentation Rate to Predict Disease Severity and Outcome in COVID-19 Patients. *Can J Infect Dis Med Microbiol.* 2022;2022.

